Navigation Links
3M™ Tegagel™ Hydrogel Wound Filler

Products3M™ Tegagel™ Hydrogel Wound Filler
Company 3M Worldwide
Item 3M™ Tegagel™ Hydrogel Wound Filler
Features 
  • Clear, hydrating gel promotes a moist wound environment which has been shown to enhance wound healing.
  • Hydrates devitalized tissue to assist autolytic debridement, eliminating need for surgical (or sharp) debridement.
  • Two styles available to meet your needs: Gel and convenient gauze pad with gel.
  • Gel is easy to apply.
  • Versatile products allow you to manage a wide range of partial- and full-thickness wounds.
    • Description Tegagel hydrogel wound filler and Tegagel hydrogel wound filler with gauze are amorphous hydrogel dressings specially formulated to help provide a moist environment that has been shown to enhance wound healing. The unique, viscous, hydrating formula meets clinical needs for management of non-draining, minimally draining and necrotic wounds.
    Info 3M Worldwide
    Customer Service: (888) 364-3577
    Web site: http://solutions.3m.com/wps/portal/!ut/p/kcxml/04_Sj9SPykssy0xPLMnMz0vM0Q9KzYsPDdaP0I8yizeIN3b00S_IcFQEAEkU7y4!

    Related medicine products :

    1. 3M™ Steri-Drape™ Extremity Drapes
    2. 3M™ Steri-Drape™ Arthroscopy Drapes
    3. 3M™ Steri-Drape™ Patient Isolation Drapes
    4. 3M™ Steri-Drape™ General Orthopaedic Surgical Packs
    5. 3M™ Tegagel™ Hydrogel Wound Filler with Gauze
    6. 3M™ Precise™ Vista Disposable Skin Stapler
    7. Clo-Sur P.A.D. Nonwoven Hydrophilic Wound Dressing
    8. Pulsavac Wound Debridement System
    9. VIGILON Primary Wound Dressing
    10. FlexiGel Strands® Absorbent Wound Dressing
    11. ClozeX Needleless Wound Closure Device
    Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 1GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 2GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 3GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 4GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 5GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 6nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 1nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 2MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 1MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 2